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p97 (also known as Cdc48, Ter94, and VCP) is an essential, abundant and highly conserved ATPase
driving the turnover of ubiquitylated proteins in eukaryotes. Even though p97 is involved in highly
diverse cellular pathways and processes, it exhibits hardly any substrate specificity on its own.
Instead, it relies on a large number of regulatory cofactors controlling substrate specificity and turn-
over. The complexity as well as temporal and spatial regulation of the interactions between p97 and
its cofactors is only beginning to be understood at the molecular level. Here, we give an overview on
the structural framework of p97 interactions with its cofactors, the emerging principles underlying
the assembly of complexes with different cofactors, and the pathogenic effects of disease-associated
p97 mutations on cofactor binding.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The covalent modification of proteins with the small protein
ubiquitin (termed ‘‘ubiquitylation”, ‘‘ubiquitination” or ‘‘ubi
quitinylation”) regulates numerous essential processes in all
eukaryotic cells [1]. In particular, ubiquitylation controls protein
degradation through three major proteolytic systems, the 26S pro-
teasome, macroautophagy, and the endolysosomal pathway [2,3].
Moreover, ubiquitylation has diverse non-proteolytic roles in mod-
ulating protein function as well as the spatial and temporal organi-
zation of protein complexes [3].
Target protein ubiquitylation involves the formation of an
isopeptide bond between the C-terminus of ubiquitin and lysine
residues of target proteins. This process requires ATP and a cascade
of three enzymatic activities, E1 (ubiquitin activating enzyme), E2
(ubiquitin conjugating enzyme), and E3 (ubiquitin protein ligase)
[1,3]. The target protein specificity of this system is primarily
determined by a large number of different E3 enzymes found in
all eukaryotes. While target proteins can be modified with one or
several individual ubiquitin molecules, in the majority of cases pre-viously conjugated ubiquitin moieties are in turn ubiquitylated,
resulting in target protein modification with ubiquitin chains of
different lengths and linkage types [3]. Ubiquitin chains can also
be subject to editing by de-ubiquitylating enzymes (DUBs), which
further increases the plasticity of ubiquitin modifications [4].
In addition to the enzymes mediating the assembly of defined
ubiquitylation marks on target proteins, the chaperone-related,
ubiquitin-selective ATPase p97 (also known as Cdc48, Ter94 and
VCP) has emerged as an important motor and regulator of many
ubiquitin-controlled cellular processes. p97 is involved in the pro-
teasomal degradation of protein quality control targets, cell cycle
regulators, transcription factors and DNA repair proteins, but also
in non-proteasomal proteolysis through macroautophagy and the
endolysosomal pathway [5,6]. Moreover, p97 mediates the non-
proteolytic mobilization of ubiquitylated proteins, e.g. transcrip-
tional regulators and SNARE proteins. Its involvement in three
major cellular proteolysis pathways makes p97 a central element
of eukaryotic proteostasis (protein homeostasis). Importantly,
mutations in the human VCP gene encoding p97 are causative of
two fatal protein aggregation diseases (‘‘proteinopathies”), Inclu-
sion Body Myopathy with Paget’s disease of the bone and Fronto-
temporal Dementia (IBMPFD) and familial Amyotrophic Lateral
Sclerosis (fALS) [7,8]. On the cellular level, both diseases are char-
acterized by cytoplasmic protein inclusions (aggregates) positive
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sis of IBMPFD patient-derived cell-lines and IBMPFDmouse models
revealed that disease-causing point mutations in VCP affect autop-
hagy and endolysosomal protein degradation [9,10].
p97 is a member of the AAA (ATPases Associated with diverse
cellular Activities) protein family and forms homohexameric,
ring-structured complexes [11,12]. It uses energy derived from
ATP hydrolysis to extract or ‘‘segregate” ubiquitylated target pro-
teins from stable protein assemblies, membranes and chromatin.
The molecular mechanism underlying this ‘‘segregase” activity is
still under debate, but is likely to rely on pronounced conforma-
tional changes induced by ATP binding and hydrolysis [6,11,12].
Since p97 is involved in highly diverse cellular processes, its segre-
gase activity must be tightly controlled in time and space. This is
achieved by a host of regulatory cofactors, which control substrate
specificity and fate, subcellular localization and the oligomeric
state of p97 [5,13,14]. In fact, the number and diversity of p97
cofactors is unique among the AAA ATPases, making p97 a prime
example of a modular system comprising a relatively unspecific
‘‘engine” and a sophisticated ‘‘tool-kit” for specific cellular tasks.
Importantly, p97 has recently been recognized as a promising
target of cancer chemotherapy [15]. Potent ATP-competitive and
allosteric p97 inhibitors have been developed and are entering
phase I clinical trials. Intriguingly, some inhibitors are specific for
p97–cofactor complexes and may prove useful in blocking specific
p97-dependent pathways in vivo [16].
In this review, we will first introduce the three-dimensional
structure and nucleotide-dependent conformational states of p97.
We will then explain in detail the molecular basis of cofactor bind-
ing as well as emerging principles governing the formation of dis-
tinct functional p97–cofactor assemblies. Finally, we will discuss
the impact of disease-causing VCP mutations on the structure of
p97 and its interactions with cofactors. More detailed information
about the cellular functions of p97 can be found in several recent
reviews [5,17–19].2. p97 structure and ATPase activity
The p97 monomer starts with the N domain (residues 1–187 in
mammalian p97), followed by the D1 (residues 209–460) and D2
(481–763) tandem ATPase domains and a disordered C-terminal
region (residues 764–806) (Fig. 1A). Two linker regions (residues
188–208 and 461–480) connect the N and D1 domains as well as
the D1 and D2 domains, respectively. From a protein taxonomy
perspective, the three structural domains can be further divided
into subdomains: The N domain forms a double W b-barrel (Nn,
residues 21–106) followed by a four-stranded b-barrel (Nc, resi-
dues 107–187), whereas each of the ATPase domains consists of
a P-loop NTPase a/b subdomain adopting a Rossman fold and a
smaller C-terminal a-helical bundle domain. The Rossman core of
the ATPase domains features, besides the classical Walker A
(P-loop; G(x)4GKT)) and Walker B (hhhhDE, h hydrophobic amino
acid) motifs, a sensor 1 asparagine residue (Asn348 and Asn624,
respectively), which assists the Walker B motif in coordinating
the attacking water molecules, and an arginine finger (Arg359
and Arg635, respectively), which stabilizes the developing negative
charge during ATP hydrolysis.
The three-dimensional structure of hexameric p97 in the
absence of cofactors has been analyzed by X-ray crystallography,
small angle X-ray scattering (SAXS) and electron microscopy
(EM). Crystal structures of full-length murine p97 in the presence
of the transition state analog ADP-AlFx at 4.7 Å resolution [20]
and in complex with ADP at 3.7 Å resolution [21] established an
overall architecture featuring two hexameric rings consisting of
the D1 and D2 ATPase domains, respectively, stacked in a headto tail arrangement, with the N domains protruding away from
the 6-fold axis, in plane with the D1 domains (Fig. 1B). The inter-
domain linkers (N–D1 and D1–D2) are each located in close spatial
proximity to the nucleotide binding site of the ensuing ATPase
domain. Both structures as well as subsequently solved structures
with various nucleotides at 3.5–4.4 Å resolution exhibited poor
electron density in the D2 domain, thus prompting a separate anal-
ysis of the isolated D2 domain [22,23]. In all full-length structures,
pre-bound ADP was invariably present in the D1 domain, whereas
the D2 domain contained the nucleotides added during crystalliza-
tion, indicative of a lower catalytic activity in the D1 domain and/
or slow exchange kinetics. Structures of full-length p97 in the apo-
state were also determined by cryo EM [24–27]. Unfortunately,
however, the resolution remained rather low (around 20 Å) even
in the latest study, perhaps suggesting that p97 poses problems
to cryo EM that cannot be overcome by recent methodological
advances in this field. One of these studies investigated structural
differences between different nucleotide states, namely ADP, ADP-
AlFx AMP-PNP and a nucleotide-free state [26]. Finally, SAXS struc-
tures were derived for the same nucleotide states [28]. In contrast
to full-length p97, the N–D1 fragment appears to be more amen-
able to high resolution structural analysis and has therefore been
extensively investigated [25,29,30], including structures of N–D1
variants carrying IBMPFD-associated point mutations [29,30] (see
below).
The p97 hexamer, at least to a first approximation, obeys C6
symmetry, not only in the conformation of its subunits but also
with respect to nucleotide occupancy where the same nucleotide
is always present in all six subunits of the D1 (typically ADP) or
D2 rings (different nucleotides). Along the sixfold axis, conically-
shaped invaginations are present in both the D1 and the D2 rings
with the one in the D2 ring being significantly more prominent,
i.e. with a larger opening and depth. Between the two rings a cen-
tral cavity exists (Fig. 1C) leaving open the possibility that at least
under certain conditions a central pore traverses the hexamer
along its sixfold axis. In the available structures of full-length
p97, however, the pore is blocked by the inward facing side chains
of the histidine residues at position 317 in the D1 ring [20]. The
contacts between adjacent subunits are quite extensive with 9%
of the monomer surface per contact with an adjacent subunit in
the AMP-PNP state and 8% in the ADP-AlFx and ADP states, in
agreement with the predominantly hexameric state of p97
reported in all biochemical and structural studies so far.
The cryo EM [26] and SAXS [28] structures of p97 in different
nucleotide states indicate large scale, nucleotide-dependent con-
formational changes. For example, the radii of gyration of the
nucleotide-free, AMP-PNP, ADP-AlFx and ADP states determined
by SAXS are 61, 57, 55 and 58 Å, respectively. Furthermore, high
speed atomic force microscopy revealed that ATP binding to the
D2 domain induces forward clockwise and backward counterclock-
wise rotational movements (23 ± 8) between the N–D1 and D2
hexameric rings [31]. The repeated back and forward rotational
movements of p97 suggest a possible way of converting the chem-
ical energy stored in ATP into mechanical energy required for the
remodeling of substrates (see below). Similar rotational move-
ments, albeit in the opposite direction, have been found in recent
cryo EM studies [27]. Of note, these conformational changes were
not observed in the corresponding crystal structures [23], where, in
general, only small variations were found, and specifically the
nucleotide-free state appeared to be significantly more compact
than in the SAXS study. This discrepancy is probably the conse-
quence of extensive crystal lattice contacts involving in particular
the D2 and N domains, which may well prevent the conformational
changes observed in solution. Nevertheless, despite these lattice
contacts, rearrangements in the relative orientation of the domains
could be observed in the crystal structures. For example, the
Fig. 1. p97 structure. (A) Domain architecture of p97 with the N domain in yellow and the two ATPase domains in blue/cyan (D1) and red/orange (D2), respectively. The
Walker A (A) and Walker B (B) motifs as well as the Sensor 1 (S1) residues and arginine fingers are indicated. Representative substrate-recruiting and substrate-processing
cofactors binding to the N domain and C-terminus of p97 are indicated. Note that phosphorylation of tyrosine residue 805 blocks cofactor binding to the C-terminus.
(B) Left: Top and side view of the full-length p97 structure, color-coded as in (A) (pdb entry 3CF3). Right: Top and side view of N domain conformational changes (pdb entries
3CF3 and 3HU3) identified in the R155H mutant (black and gray). (C) Molecular surface representation of the p97 axial channel viewed from the side. For clarity, three
monomers have been omitted. His317 in the D1 domain is shown in green. Residues in the D2 domain are colored as follows: Positively charged (Arg586, Arg599) in blue and
hydrophobic residues in yellow (Trp551, Phe552).
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is 11, but also for these intra-protomer domain rearrangements it
is unclear whether crystal contacts prevented more significant
changes. Crystal structures of N–D1 fragments of the wild-type
and IBMPFD-associated mutant variants, however, did reveal dra-
matic conformational changes in the position of the N domain
[29]. It undergoes a displacement by 12 Å and a rotation of more
than 90 from its position in plane with the D1 ring (‘‘down” con-
formation) as observed in all full-length crystal structures as well
as in the ADP state of wild-type and IBMPFD mutant N–D1 frag-
ments, to an out of plane (‘‘up”) conformation present in N–D1
structures of IBMPFD mutants in the presence of ATPcS (Fig. 1C).
Coupled to this large rearrangement is a loop-to-helix transition
in the linker connecting the N and D1 domains. While currently
no crystal structure of the wild-type N–D1 fragment in the pres-
ence of ATPcS is available, SAXS studies suggest a similar
nucleotide-dependent motion [29].
Even though the full-length crystal structures presumably do
not reflect the full scale of conformational changes occurring in
solution, they provide important insights into local structural
changes in the vicinity of the nucleotide bound to the D2 domain.
These changes affect the sensor 1 loop, the P-loop, the D1–D2
linker, the Arg finger and residues lining the central pore of p97.
The latter include His317, which obstructs the pore, the aromatictandem Trp551 and Phe552, located well within the D2 pore, and
the basic residues Arg586 and Arg599, which are positioned at
the entrance to the D2 pore (Fig. 1D) [23]. Mutational studies
suggest that these pore-lining residues play critical roles for the
segregase activity of p97 [32] and were interpreted to indicate that
substrates do not pass through the D1 pore but instead interact
with the much wider D2 pore. The cryo EM structures, on the other
hand, indicate that the pore width changes during the ATPase cycle
[26,27]. In particular, the pore appears much wider in the AMP-
PNP state, consistent with the possibility that substrates are
translocated along the central pore across the double D1–D2 ring,
as in the case of Clp-type AAA ATPases possessing unfolding
activity [12]. In this context it is interesting to note that molecular
dynamics simulations of a substrate threading through the p97
pore suggest an energetically more favorable transport in the
direction from the D1 to the D2 ring compared to the opposite
direction [33]. However, in contrast to Clp-type unfoldases, no
direct experimental evidence could be obtained that p97
substrates are threaded through the entire length of the central
pore. An unfoldase activity of p97 was so far only observed upon
simultaneous deletion of the N domain and mutation of D1 ring
pore residues to tyrosines [34,35], perhaps suggesting that p97
evolved to use a mechanism of substrate turnover that is distinct
from a Clp-like threading mechanism.
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(i.e. within the same subunit) and an intermolecular (i.e. between
different subunits) manner. With respect to the intramolecular
communication this involves the D1 and D2 subunits of the same
polypeptide chain for which it could be shown that nucleotide
binding to one ATPase domain is essential for the activity of the
other domain [36,37]. The intermolecular effect is directly obvious
from the structures: ATP is bound at the interface of two adjacent
protomers, and the Arg finger is of critical importance for sensing
the nucleotide state in trans [38]. As to the effects of these
intramolecular and intermolecular signaling mechanisms, the
communication between the D1 and D2 rings is inhibitory in nature
so that ATP hydrolysis does not occur simultaneously in both
domains (negative cooperativity) [39]. In contrast, the communica-
tion within each ring exhibits positive cooperativity since the Arg
finger is essential for the catalytic mechanism [32,40]. Besides the
Arg finger, the D1–D2 linker from the neighboring subunit has also
been suggested to be involved in intermolecular communication
within the p97 hexamer [41,42].
A recent systematic study of IBMPFD-causing p97 variants
carrying point mutations at the N–D1 interface revealed increased
ATPase activities [43]. The authors also showed for wild-type p97
that ATP hydrolysis by the D2 ring is suppressed in the coplanar/
locked conformation (down conformation) of the N domain. When
the N domain is released from the D1 plane and adopts a flexible
state above the D1 ring (up conformation), D2 is competent for
ATP hydrolysis. Experimental evidence for such a flexible state
was provided by a cryo EM structure of the IBMPFD-causing
A232E variant in which the N domains are indeed located above
the D1 ring and interact with each other [43].
3. p97–cofactor interactions
p97 can interact with a large number of cofactors that regulate
its function by recruiting it to different cellular pathways [5,17,44].
So far, about 40 cofactors have been identified in mammals, and
the number is still growing. Most of the cofactors interact with
the N domain of p97, while a small number binds to the
C-terminal tail. Despite the large number of cofactors, the majority
interacts via a small number of conserved binding modules (Fig. 2).
3.1. Interactions with the N domain
Cofactors interact with the N domain either via ubiquitin-
related UBX (ubiquitin regulatory X) or UBXL (UBX-like) domains
or via three short, linear binding motifs called VIM (VCP-
interacting motif), VBM (VCP-binding motif) and SHP box (also
called binding site 1 (BS1)) [44] (Fig. 2A–C). Functionally, these
binding partners can be divided into substrate-recruiting and
substrate-processing cofactors (Fig. 1A).
3.1.1. UBX and UBXL domains
The UBX domain is a module comprising approximately 80
amino acids and displays a b-grasp fold (b–b–a–b–b–a–b) closely
resembling the structure of ubiquitin [45]. UBX domain containing
proteins constitute the largest family of p97 cofactors [46,47]. A
subset of UBX domain proteins is characterized by the presence
of an ubiquitin-associated (UBA) domain, which mediates binding
to ubiquitylated substrates [48,49]. These UBA-UBX proteins serve
as prototypical substrate-recruiting cofactors or substrate ‘‘adap-
tors” of p97. So far, 13 UBX domain-containing proteins have been
identified in mammals, all of which, with the exception of UBXD1
(see below), have been demonstrated to bind to p97 [46,47,49]. In
addition, the related UBXL domain has been identified in a few
p97 cofactors including the NPL4 subunit of the heterodimericUFD1-NPL4 cofactor [50] and the two DUBs OTU1/YOD1 [51] and
VCIP135 [52]. Due to their higher resolution, we will focus the fol-
lowing discussion on the UBX and UBXL domains of FAF1 and
OTU1, respectively.
Molecular insights into p97-UBX domain interactions were
obtained by crystal structures of the N domain in complex with
the UBX domains of p47 [53] and FAF1 [54–56] (Fig. 2B). The
FAF1 UBX domain interacts with the N domain via a conserved
arginine from strand b1 and a Phe-Pro-Arg tripeptide located in
the S3/S4 loop connecting strands b3 and b4. These four residues
form the highly conserved R. . .FPR signature motif of UBX proteins
[45]. The UBX domain inserts its S3/S4 loop into the hydrophobic
cleft separating the two subdomains of the N domain, which repre-
sents a binding pocket common to the UBX and UBXL (see below)
domains. Importantly, the FPR turn exhibits a cis-proline configura-
tion and adopts a rarely observed cis-Pro touch-turn structure (also
known as FcisP touch-turnmotif) [57]. The cis-proline configuration
is essential for N domain binding as it allows the aromatic ring of
the phenylalanine to insert into the hydrophobic interdomain cleft
[54–56]. In contrast, the trans-isomer would either produce severe
steric clashes or prevent the phenylalanine residue from reaching
the binding cleft. Interestingly, crystal structures of the free FAF1
UBX domain revealed that the S3/S4 loop displays conformational
variability with the critical proline either in cis- or trans-
configuration [54,57], suggesting an induced fit mechanism upon
N domain binding. In addition to the phenylalanine, both arginine
side chains of the R. . .FPR motif reach deep into the p97-binding
pocket to anchor the UBX domain and to stabilize the complex by
essential hydrophobic and electrostatic interactions.
The UBXL domains adopt a structure similar to the UBX domain
despite a low sequence identity and the lack of the UBX signature
motif [58]. The structure of the UBXL domain of NPL4 has been
solved by NMR, and based on chemical shift perturbation analysis
a structural model for the N domainUBXL complex has been cal-
culated [59] (Fig. 2B). Recently, the crystal structure of the yeast
OTU1 UBXL domain in complex with the N domain of p97 has been
solved, thus allowing for a detailed structural comparison of UBXL
domains (NPL4, OTU1) and UBX domains (p47, FAF1) [58] (Fig. 2B).
Although the UBX and UBXL domains share structural homology at
the Ca level, the electrostatic surfaces are quite different between
both families. While members of both families bind to the same
site of the N domain, the interaction modes are specific for each
domain. The most intriguing differences are found in the confor-
mation of the S3/S4 loop. The UBXL domain of NPL4 resembles
ubiquitin rather than UBX with respect to the length of its S3/S4
loop, which is extended by six residues, however, in contrast to
ubiquitin it harbors a 310-helix. This loop provides specific contacts
with p97, which distinguishes it from ubiquitin and the UBX
domain. In the OTU1 UBXL domain the S3/S4 loop contains the
motif YPP, with the central proline found in cis-configuration, sim-
ilar to the corresponding proline in the FPR loop of the UBX
domain. In contrast to the UBX domain, however, the central pro-
line in OTU1 is involved in a stacking interaction with the preced-
ing tyrosine, resulting in a different conformation of the S3/S4 loop.
In addition, the first arginine of the R. . .FPR UBX signature motif is
replaced by threonine in the OTU1 UBXL domain. Taken together,
the UBX and UBXL domains bind in similar orientations to the N
domain of p97 while exhibiting unique recognition features.
3.1.2. The VCP-interacting motif
The VCP-interaction motif (VIM) (Fig. 2A), a linear, a-helical
polypeptide stretch composed of positively charged flanking resi-
dues separated by moderately hydrophobic alanine residues, was
originally identified in the E3 ubiquitin ligase gp78 (also known
as AMFR, Autocrine Motility Factor Receptor) [60] and in SVIP
Fig. 2. p97 binding modules. (A) Sequence alignment of the SHP box, the VIM and the VBM (all protein sequences are frommammals). (B) Ribbon representations of the FAF1-
UBX (pdb entry 3QQ8, colored in gold), NPL4-UBXL (pdb entry 2PJH, colored in blue) and OTU1-UBXL domains (pdb entry 4KDI, colored in cyan) in complex with the p97 N
domain (molecular surface colored in gray). Details of the key interaction in the region of the S3–S4 loop are shown. (C) Ribbon and surface representation of the p97 N
domain (colored in gray) in complex with the gp78 VIM peptide (pdb entry 1TIW, colored in green). Key interactions with the conserved arginines are shown. (D) Ribbon
representation and molecular surface colored according to its electrostatic potential (electropositive in blue, electronegative in red, contoured at ±5 kT) of the PNGase PUB
domain in complex with the C-terminal residues of p97 in stick representation (pdb entry 2HPL, colored in orange). (E) Ribbon representation and molecular surface colored
according to its electrostatic potential (electropositive in blue, electronegative in red, contoured at ±5 kT) of the PLAA PUL domain in complex with the C-terminal residues of
p97 in stick representation (pdb entry 3EEB, colored in orange).
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gp78-mediated ER-associated protein degradation [61,62]. A sub-
sequent bioinformatic search defined a minimal VIM consensus
sequence and identified several additional VIM-containing pro-
teins [63]. These include ANKZF1 (ANKyrin repeat and Zinc Fingerdomain-containing-1, also known as ZNF744 or Vms1), a protein
that has been implicated in mitochondrial protein degradation
[64]; the UBX protein UBXD1, involved in sorting of ubiquitylated
cargo in the endocytic pathway [10]; AIRAPL (Arsenite Inducible
RNA Associated Protein Like Protein, also known as ZFAND2B), an
A. Buchberger et al. / FEBS Letters 589 (2015) 2578–2589 2583ER membrane-anchored protein which associates with and regu-
lates the function of the 26S proteasome under arsenite stress
[65]; SelS (also called VIMP, VCP-Interacting Membrane Protein),
a protein involved in the recruitment of p97 to the ER membrane
[66]; and the yeast protein Wss1, a metalloprotease involved in
DNA–protein crosslink repair [67]. With the exception of SelS it
was shown that these proteins interact via their VIM with p97
[63,64,67–69]. VIM containing cofactors can be grouped into two
subfamilies [63] (Fig. 2A): (i) ‘‘RAAR” proteins, which contain the
consensus sequence RX5AAX2R with two conserved arginine resi-
dues separated by a hydrophobic amino acid stretch including
two conserved alanine residues as found in gp78, ANKZF1, SVIP
and SelS, and (ii) ‘‘AAR” proteins as found in UBXD1 and AIRAPL,
which contain the consensus sequence AAX2R but lack the first
conserved arginine.
The crystal structure of the p97 N domain in complex with a
gp78-derived peptide spanning the VIM revealed that the VIM
indeed adopts an a-helix and that it inserts into the hydrophobic
pocket formed between the two subdomains on the N domain
[68] (Fig. 2C). Besides the two conserved arginine residues of the
signature motif, the VIM of gp78 contains a third, non-conserved
arginine amino-terminal of the first consensus arginine (RRX5-
AAX2R). All three arginine residues are important for binding, with
the carboxy-terminal arginine being most critical. These arginines
are not only involved in electrostatic interactions but also provide
important hydrophobic contacts via their long aliphatic side chain
regions. A detailed comparative study of VIM proteins from both
subfamilies revealed that all bind to the hydrophobic interdomain
cleft of the N domain [68]. A conserved binding mode of RAAR pro-
teins is also supported by an NMR chemical shift analysis of the
interaction of the ANKZF1 VIM with the N domain [63]. The bind-
ing mode of RAAR proteins involves the positively charged flanking
residues separated by hydrophobic residues and results in a high
affinity interaction [68]. However, differences due to variations in
the amino acid composition are observed that translate into
changes in affinity and might trigger a slightly altered orientation
of the a-helix, thus resulting in a modified binding specificity. For
example, despite a high degree of sequence homology with the
VIMs of gp78 and ANKZF1, the RAAR protein SVIP requires for high
affinity binding not only the N domain of p97, but also the N–D1
linker region and the adjacent D1 domain [68]. This is probably
the consequence of the longer, VIM-containing a-helix in SVIP
[70] and indicates that additional residues can determine affinity
and specificity. In contrast, proteins of the AAR subfamily, which
lack the first positively charged residue, bind with much lower
affinity, and the interaction is mainly driven by hydrophobic con-
tacts [68]. While it is conceivable that this binding mode with only
one arginine residue as anchor allows for a high degree of rota-
tional flexibility, this hypothesis has to await further support by
a corresponding high resolution structure.
3.1.3. The VCP-binding motif
The VCP-binding motif (VBM) was first identified in the DUB
ataxin-3 (ATX3) and the ubiquitin ligase UBE4B [71] and has sub-
sequently also been found in the ubiquitin ligase HRD1 [72], in the
ubiquitin-dependent ER-resident rhomboid protease RHBDL4 [73],
and in NUB1L, which is involved in the proteasomal degradation of
NEDD8 [70,74]. The VBM is characterized by a core of four posi-
tively charged residues (Arg/Lys) with a highly conserved arginine
at position four (consensus sequence EhRRRRL; h, hydrophobic
amino acid) (Fig. 2A). Mutational studies of the HRD1, ATX3 and
UBE4B VBM motifs revealed that only the first and the last Arg/
Lys residues are strictly required for p97 binding [72]. Solution
structures of the HRD1 and NUB1L VBMs revealed an a-helix with
the two critical positively charged residues located on the sameface [70]. While the C-terminal leucine residue was found to be
critical for p97 binding of the HRD1 and UBE4B VBMs, it is replaced
in ATX3 by a glutamate residue that is not involved in p97 binding
[72]. The function of the highly conserved N-terminal glutamate
residue has not been studied so far. The VBM exhibits a roughly
10-fold lower affinity to the p97 N domain than the a-helical VIMs
of gp78 and SVIP [70]. This may be due to the VBM forming a
shorter helix and lacking additional positively charged residues
besides the clustered arginines, leading to a more restricted bind-
ing interface compared to the VIM, where the positively charged
residues are separated into two regions. Consistent with overlap-
ping binding sites of VBM and VIM at the hydrophobic interdomain
cleft of the p97 N domain, a mutually exclusive binding of the VBM
from HRD1 and the VIM from SVIP was demonstrated [70].
3.1.4. SHP box/BS1
The SHP box binding motif (also called binding site 1, BS1) was
initially identified in the yeast proteins Shp1 (the yeast ortholog of
p47), Ufd1, Wss1 and the Derlin homolog Dfm1 [75,76], as well as
in mammalian p47 and UFD1 [50]. It is a short hydrophobic
sequence stretch containing two invariant glycine residues and is
characterized by the consensus sequence FxGxGx2h (x, any amino
acid, h, hydrophobic amino acid) (Fig. 2A). The binding sequence is
quite variable and typically found in unstructured regions of p97
cofactors. In mammals, the motif is found in the SEP (Shp, eyes-
closed, p47) domain-containing UBX proteins p47, p37, UBXD4
and UBXD5, where it is located N-terminally of the UBX domain
[46], to which it is connected via a mainly unstructured linker. Fur-
ther mammalian members are the UBX protein TUG (also known as
ASPL) [77], UFD1 [50], DVC1 (also called Spartan, a homolog of
yeast Wss1), a proteolytic enzyme that functions in DNA repair
coupled to DNA replication [67,78], and the Derlin proteins DER1
and DER2 involved in endoplasmic reticulum associated protein
degradation (ERAD) [66,79–81]. Currently, only limited structural
information on the SHP box-p97 interaction is available, and the
exact binding site of the SHP box on the p97 N domain remains
unclear. While NMR data suggest that the binding region of the
SHP box of UFD1 on the N domain partially overlaps with the bind-
ing site for the UBXL domain of NPL4 [59], pull-down experiments
demonstrated that SHP box binding to p97 does not interfere with
the binding of UBX/UBXL domains, suggesting different binding
sites [50].
3.2. Interactions with the C-terminal tail
So far, the PUB (PNGase/UBA or UBX containing proteins; also
known as PUG) and PUL (PLAP, Ufd3p, and Lub1p) domains are
the only defined structural domains known to interact with the
C-terminal tail of p97. Both modules had originally been linked
to the ubiquitin system based on bioinformatic analyses [82–84].
3.2.1. The PUB domain
The PUB domain consists of a short, three-stranded b-sheet
packed onto an a-helical core [85]. Three PUB-domain containing
proteins have been described so far in humans and all interact with
the p97 C-terminal tail: PNGase (peptide N-glycanase) [85,86],
which is involved in the deglycosylation of misfolded glycoproteins
[87], the UBX protein UBXD1 [68,85,88], and HOIP (HOIL-1-
interacting protein) [89–91], the catalytic subunit of the E3 ubiqui-
tin ligase LUBAC, which catalyzes the assembly of linear ubiquitin
chains [92].
Molecular insights into the interaction of the PUB domain with
p97 were revealed by crystal structures of the PNGase and HOIP
PUB domains in complex with peptides comprising the five and
four, respectively, C-terminal residues of p97 called PIM (PUB
2584 A. Buchberger et al. / FEBS Letters 589 (2015) 2578–2589Interacting Motif) [86,91] (Fig. 2D). The PUB-PIM complex is stabi-
lized by a combination of hydrophobic and electrostatic interac-
tions, with a key interaction mediated by insertion of the
hydrophobic side chain of Leu804 and the aromatic side chain of
Tyr805 of p97 into a hydrophobic pocket of the PUB domain called
the U-Y pocket [91]. Interestingly, phosphorylation of the strictly
conserved tyrosine residue within the PIM (Tyr805 in p97) com-
pletely blocks the interaction of p97 with the PUB domain and with
the PUL domain of Ufd3 (see below) [86,90,91,93]. Thus, tyrosine
phosphorylation appears to be a conserved mechanism to control
protein–protein interactions of the C-terminal tail of p97.
3.2.2. The PUL domain
The PUL (PLAP, Ufd3p, and Lub1p) domain of human PLAA
(phospholipase A2-activating protein; also know as PLAP) and its
yeast homolog Ufd3/Doa1 has been shown to mediate binding to
p97/Cdc48 [86,94,95]. The PUL domain adopts an extended fold
composed of six armadillo repeats connected by short loops where
each repeat is composed of three helices. The binding site of the
p97 C-terminal tail on the PUL domain is still controversial. A
detailed mutational and biochemical study of the yeast Ufd3 PUL
domain revealed a conserved binding site on a concave surface,
which represents the primary protein binding site of Armadillo
domains [96]. This area forms a continuous, positively charged
electrostatic surface, which could complement the highly nega-
tively charged C-terminus of Cdc48/p97. Consistent with these bio-
chemical data, Ufd3 variants with point mutations in this region
failed to interact with Cdc48 in vivo. However, a crystal structure
of the human PLAA PUL domain in complex with a p97 C-
terminal peptide (TEDNDDDLYG) revealed a different binding site
in an adjacent hydrophobic groove [97] (Fig. 2E). In this structure,
only Leu804 and Tyr805 point into a hydrophobic pocket in a con-
formation that is strikingly similar to that when in complex with
the PNGase PUB domain. Unfortunately, only the last four residues
of the p97 peptide resembling the PIM (see above) are ordered in
the crystal structure. It is therefore possible that the remaining
negatively charged and polar residues reach into the neighboring
positively charged ridge that has been identified by biochemical
studies [96]. Thus, the binding mode between the PUL domain
and the PIM of Cdc48/p97 may well be conserved from yeasts to
mammals.
3.3. Non-canonical binding domains/motifs
The number of cofactors that associate with p97 is still growing.
Although so far all cofactors bind either to the N domain or to the
extreme C-terminus of p97, cofactor associations with the D2
domain are imaginable which could allosterically influence the
translocation properties of the D2 domain. Furthermore, it would
not be surprising if in the future additional binding domains or
interaction motifs were identified. For example, neurofibromin 1
(NF1), a protein that is involved in synaptogenesis, has been shown
to interact with the two ATPase domains (D1D2) in the absence of
the N domain and the C-terminal tail via its LRD domain (leucine
rich repeat domain) [98]. This domain neither displays structural
similarity to any of the known p97 interacting domains nor does
it contain any of the linear binding motifs. Other examples are
the CSN5 subunit of the COP9 signalosome, which is proposed to
interact via its MPN domain with the N domain [99] or SelS/VIMP,
which instead of using its VIM binds via two proline residues [100].4. Cofactors define functional p97 assemblies
One of the key questions regarding the biological function of
p97 is how this highly abundant ATPase participates in so manydissimilar processes. The underlying principle for this functional
diversity of p97 is its ability to associate with a large variety of
cofactors mediating specificity for subcellular localization, path-
ways and/or substrates. To ensure that cofactor binding results in
defined, productive p97 assemblies with specific cellular functions,
it must be tightly controlled by multiple regulatory mechanisms.
While a complete understanding will require further structural,
biochemical and cellular studies of p97–cofactor interactions,
some of the regulatory mechanisms underlying ordered cofactor
binding, including competition for overlapping binding sites on
the N domain, bipartite binding, hierarchical binding of major
and auxiliary cofactors, and nucleotide-dependent conformational
changes altering cofactor assembly have been described and are
discussed below.
4.1. Competition for binding sites
As discussed above, the linear VIM and VBM motifs as well as
the UBX and UBXL domains all bind to partially overlapping sites
at the hydrophobic intersubdomain cleft of the p97 N domain,
despite the absence of significant sequence similarity between
them (Fig. 3A). This demonstrates that one N domain and hence
one p97 protomer can only interact with one of these proteins at
any given time, reducing the complexity of cofactor interactions
to a combinatorial problem of six N domains per p97 hexamer.
Competition for N domain binding has been experimentally veri-
fied for various combinations of cofactors possessing different
binding modules, e.g. SHP/UBX – SHP/UBXL (p47 – UFD1-NPL4)
[50,101], SHP/UBX – VIM (p47-UBXD1) [88], VIM – VBM (SVIP –
HRD1) [70], VIM – SHP/UBXL (gp78 – UFD1-NPL4) [60]. The VIM
protein SVIP is remarkable, as it is currently the only known p97
cofactor that binds with high affinity to all six N domains [68]
and prevents the association of additional cofactors (see below).
Consistent with its function as an inhibitor of the ERAD pathway
[62] and its regulatory role in p97 subcellular localization and
autophagy [102], SVIP forms a distinct complex with p97 and is
an efficient competitor of the major N domain targeting cofactors
UFD1-NPL4 and p47 [61,68,70]. It should nevertheless be noted
that the basic ability of cofactors or their isolated binding modules
to compete for p97 binding typically has been tested in biochemi-
cal titration experiments using purified proteins and peptides. The
outcome of competitive binding in living cells is likely to be much
more complex, as it depends, among other factors, on the relative
intracellular concentrations and binding kinetics of many simulta-
neously present cofactors.
Competitive binding has also been described for the yeast
substrate-processing cofactors Ufd2 and Ufd3, which bind to
overlapping regions at the C-terminus of Cdc48 [95,103], but has
not yet been analyzed for mammalian PUB and PUL domain
containing cofactors.
4.2. Bipartite binding modes
Several p97 cofactors, including the three major cofactors p47,
UFD1-NPL4 and UBXD1, contain more than one p97 binding
module, enabling them to interact with p97 in a bipartite manner
[50,59,63,88]. For p47, this involves binding via the UBX domain
and the SHP box, whereas the UFD1-NPL4 heterodimer interacts
via the UBXL domain of NPL4 and the SHP box of UFD1. Since p47
is a stable trimer, the bipartite bindingmode results in the symmet-
ric binding of three p47 subunits, which occupy all six N domains of
the p97 hexamer [104]. By analogy, a similar symmetric, bipartite
binding mode of the p47-related cofactors p37, UBXD4 and UBXD5
can be expected. In contrast, only one UFD1-NPL4 heterodimer
binds to two adjacent protomers of a p97 hexamer [105]. Impor-
tantly, these binding modes provide the structural basis for the
Fig. 3. Regulation of p97 cofactor assembly. (A) Competition for binding sites. Left, Ribbon representation of p97 and its cofactor binding site located at the intersubdomain
cleft of the N domain (Nn in white, Nc in black, D1 in blue, D2 in red). Right, Ribbon representations together with the molecular surface of the p97 N domain in complex with
the VIM of gp78 (pdb entry 3TIW, colored in green), FAF1-UBX (pdb entry 3QQ8, colored in gold) and NPL4-UBXL (pdb entry 2PJH, colored in blue). (B) Model for the bipartite
binding of major p97 cofactor assemblies.
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UFD1-NPL4 to p97 [50,101], which is evolutionarily conserved
and defines the two best-characterized p97 assemblies with
distinct cellular functions. The p97UFD1-NPL4 complex is required in
a number of proteasomal degradation pathways such as ERAD,
where it drives the dislocation of polyubiquitylated substrates from
the ER membrane into the cytosol, degradation of proteins associ-
ated with chromatin and the outer mitochondrial membrane, and
of important regulators of cell cycle progression and signal trans-
duction (reviewed in [5,17–19]). In contrast, the p97p47 complex
functions mainly in proteasome-independent processes such as
autophagy and the post-mitotic reassembly of Golgi stacks and
the nuclear envelope [5,17,106].
In higher eukaryotes, the p97UBXD1 complex represents a third,
distinct p97 assembly with so far poorly defined function(s) in
endolysosomal trafficking [10]. Even though UBXD1 belongs to
the UBX family of p97 cofactors, it does not bind p97 via its UBX
domain because the R. . .FPR signature motif (see above) is replaced
by SGG. Instead, UBXD1 uses a bipartite binding mode where its
PUB domain and VIM interact with the C terminus and N domain
of p97, respectively [63,88]. This binding mode is unique among
p97 cofactors in that the two major binding sites of p97, the N
domain and the C terminus, are simultaneously contacted by a sin-
gle cofactor, which presumably will restrict the conformational
flexibility of p97. Similar to p47, isothermal titration calorimetry
experiments indicate that UBXD1 binds as a trimer [68], which
provides a rationale for the observed mutually exclusive binding
with p47 and UFD1-NPL4 (Fig. 3B).
Even though the importance of bipartite binding modes for the
assembly of the three major p97 complexes is well-established, itis not known whether the cofactors remain stably associated via
both binding modules all the time. It is conceivable that ATP
hydrolysis and/or substrate binding induce conformational
changes that trigger dissociation at one site and lead to an
increased conformational flexibility of the cofactor for subsequent
catalysis. Such a model would be in accordance with the conforma-
tional changes observed in EM studies of p97UFD1-NPL4 in different
nucleotide states, where the heterodimer was found to be bound
either via two binding sites in the apo state or one binding site
in the ADP bound state [107]. EM studies of the p97p47 complex
in different nucleotide states also suggest that during ATP hydrol-
ysis binding of trimeric p47 via its UBX domains involves only
every second N domain in the ADP bound state or all six N domains
with the UBX domain and its upstream linker bound between two
adjacent N domains in the presence of AMP-PNP [104].
4.3. Higher order assemblies
Since only one heterodimeric UFD1-NPL4 cofactor binds to two
adjacent protomers within the p97 hexamer, further cofactors
could potentially bind to vacant N domains. Indeed, it was shown
that immunoprecipitates of the UBA-UBX proteins FAF1, UBXD7,
UBXD8 and SAKS1 contained not only p97, but also UFD1-NPL4
[49], an observation that is consistent with the existence of
higher-order p97–cofactor complexes. A similar observation was
made in yeast where the UBA-UBX protein Ubx2 was found to exist
in a Cdc48Ufd1-Npl4-Ubx2 complex [108]. These observations led to
the concept of hierarchical cofactor binding where the general
activity of the Cdc48/p97Ufd1-Npl4 complex in proteasomal degrada-
tion pathways is further specified by the binding of additional,
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cofactor binding could be demonstrated directly with purified
recombinant proteins [54,56]. Binding of FAF1 to p97 required
the presence of UFD1-NPL4, resulting in the formation of a com-
plex with a stoichiometry of 6:1:1 (p97:UFD1-NPL4:FAF1). Since
no direct interaction of FAF1 with UFD1-NPL4 was observed in
the absence of p97, it is conceivable that the binding of UFD1-
NPL4 induces an asymmetry in the p97 hexamer such that only
one of the vacant p97 N domains interacts tightly with FAF1.
According to this model, FAF1 binding would strictly depend on
the presence of the UFD1-NPL4 cofactor, but would not have to
occur adjacent to the UFD1-NPL4 heterodimer. In one of these
studies, UBXD7 was shown to also require UFD1-NPL4 for p97
binding [54].
In a recent study, however, the concept of a hierarchical binding
of UFD1-NPL4 and FAF1 to p97 was challenged. According to an EM
structure of FAF1 in complex with p97, FAF1 binds as a trimer on
top of the p97 ring [109], reminiscent of the p97–p47 complex
exhibiting a 6:3 stoichiometry described above. The reason for
the conflicting data on the ability of FAF1 to bind p97 in the
absence of UFD1-NPL4 in vitro is unclear. However, siRNA-
mediated depletion of UFD1-NPL4 in HeLa cells almost completely
abolished the co-immunoprecipitation of p97 with FAF1, suggest-
ing that UFD1-NPL4 is indeed required for the stable binding of
FAF1 to p97, in accordance with the hierarchical cofactor binding
model [56]. While it presently cannot be ruled out that an UFD1-
NPL4-independent p97FAF1 complex can exist in vivo, further stud-
ies are required to determine physiological conditions supporting
its assembly and to identify potential specific cellular functions.
In addition to the UBA-UBX proteins discussed above, the UFD1-
NPL4 heterodimer was also found in quaternary complexes with
p97 and Otu1/YOD1 [51,58], NUB1L [74] and SelS/VIMP [66]. Of
these, only the p97UFD1-NPL4-OTU1 complex has been studied in more
detail. In vitro binding and EM studies showed that only one OTU1
molecule is recruited into the p97UFD1-NPL4 complex [58], thus
forming an oligomer with a stoichiometry of 6:1:1 similar to the
p97UFD1-NPL4-FAF1 complex discussed above. However, no hierarchi-
cal binding was observed, indicating an independent binding mode
and suggesting that hierarchical binding may be restricted to
substrate-recruiting cofactors of the UBA-UBX type.
The potential of the other two major p97 complexes, p97p47 and
p97UBXD1, to form higher order complexes has not been explored
yet. However, it was proposed that the DUB VCIP135 forms an
unstable ternary complex with p97p47 during post-mitotic Golgi
reassembly, where p47 would be associated with p97 via only
one of its two binding sites [52]. Given that the UBX domain of
p47 and the UBXL domain of VCIP135 compete for the same
binding site on the p97 N domain, this might indicate that in the
ternary p97p47-VCIP135 complex one or more p47 subunits stay
associated with p97 via their SHP box.
4.4. Nucleotide-dependent control of cofactor interactions
The ability to interact with a large number of cofactor proteins
in a highly regulated manner is critical for p97 to perform its
diverse cellular functions. As described above, the N domains in
wild-type p97 exist in a tightly regulated, mixed arrangement of
up and down conformations (also called ‘‘locked” and ‘‘flexible”
conformation, respectively) [27,43]. Since N domains are largely
responsible for p97 interactions with various adaptor proteins,
their conformational flexibility is believed to be critical for p97
to properly handle substrates bound to adaptor proteins. Although
nucleotide-dependent N domain movements of p97 suggest that a
mutual influence of cofactor binding and ATP binding or hydrolysis
could exist [104], experimental data are still limited. Cryo-EM
studies of the p97p47 [104], p97UFD1-NPL4 [107] and p97FAF1 [109]complexes revealed that cofactor binding involves multiple N
domains, and in all structures those N domains that are involved
in cofactor binding are in the up conformation. A common model
of cofactor binding to p97 has been proposed [109], according to
which a relocation of the N domain during the ATP hydrolysis cycle
from the up to the down conformation could provide the force
necessary for target protein disassembly.
Furthermore, it was shown that ATP binding to the D1 domain
regulates the recruitment of adaptor proteins to the N domain,
which is triggered through binding rather than hydrolysis of ATP
[110]. ATP was found to exert differential effects by strengthening
the binding of UFD1-NPL4 while not affecting the binding of p47,
and therefore significantly enhancing the capacity of UFD1-NPL4
to compete with p47 for p97 binding. Conversely, it has been
demonstrated that cofactors affect the p97 ATPase activity in dif-
ferent ways: p47 and the related protein p37 are inhibitory and
activating cofactors, respectively [111,112], whereas UFD1-NPL4
[111] and UBXD1 did not show an effect [113].
Recently, the link between the regulation of p97 ATPase activity
by cofactors has been studied in more detail for p37 and p47 [112].
Zhang et al. identified a region of about 25 unstructured amino
acids in p47 that is not involved in p97 binding and is missing in
p37, which is responsible for the inhibitory effect of p47. In the
D1 domain of each p97 monomer two ADP-bound states exist in
a dynamic equilibrium: the ADP-locked state containing pre-
bound, difficult-to-remove ADP [28,114], and the ADP-open state
where ADP has a reduced affinity to the D1 site and is ready to
be exchanged [29]. In the wild-type protein, the equilibrium is in
favor of the ADP-locked state, whereas in IBMPFD mutants (see
below), the ADP-open state is prevalent. p47 binding to p97
probably promotes an ADP-locked state, which prevents ATP from
binding and consequently inhibits the activity of both the D1 and
D2 domains. In contrast, p37 binding to the N domain most likely
induces conformational changes which convert the D1 domain into
the ADP-open state that allows ATP binding to D1, which in turn
activates the D2 domain. These findings suggest that distinct
cofactors can induce different conformational changes in N–D1
that regulate ADP/ATP binding to the D1 domain, which in turn
controls both the D1 and D2 ATPase cycles [112].
Importantly, IBMPFD-associated p97 mutant proteins exhibit a
dysregulation of the N domain conformational equilibrium as a
consequence of abnormal nucleotide binding to the D1 domain
[30]. Due to an altered inter-subunit communication in IBMPFD
mutants the D1 domains fail to regulate their respective
nucleotide-binding states as evidenced by a lower amount of
pre-bound ADP and weaker affinity for ADP, resulting in a better
accessibility for ATP in comparison to the wild-type protein
[29,30]. The altered conformational equilibrium of the N domain
in p97 disease mutants is accompanied by elevated ATPase activi-
ties in vitro [43,115,116] and altered interactions with some but
not all cofactors in cells, which has been proposed to be key to
the pathogenesis of IBMPFD [10,116–118] (for a recent review
see [119]). Specifically, increased amounts of p47, UFD1-NPL4,
and ataxin-3, but decreased amounts of UBXD1 and UBE4B have
been found. Interestingly, the decreased binding to UBXD1 is asso-
ciated with a blockage of the endolysosomal trafficking of caveolin
1 [10]. Although disease mutants and wild-type p97 interact with
both cofactors in a similar manner in vitro, disease mutants no
longer can be activated by p37, but are still inhibited by p47
[112]. In disease mutants the described conformational changes
for the wild-type protein (see above) are already induced, as they
are in the active ADP-open state, which might explain why no
additional activation can be observed in these mutants with p37.
In contrast, the inhibitory effect of p47 might be the consequence
of promoting the ADP-locked state that prevents ATP binding as
described for the wild-type protein (see above). Taken together,
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show that cofactors play a critical role in controlling p97 ATPase
activity, and suggest that a lack of cofactor-regulated communica-
tion may contribute to p97-associated disease pathogenesis [112].
5. Conclusion
The number and complexity of p97–cofactor interactions is con-
ceptually and experimentally challenging. While significant pro-
gress has been made in understanding the structural and
mechanistic basis of cofactor binding, important open questions
remain. For instance, a complete inventory of all physiologically
relevant, distinct p97–cofactor assemblies is still lacking. How
many major p97 complexes exist – just the known three
(p97UFD1-NPL4, p97p47, p97UBXD1), or are one or several more await-
ing discovery? Is p97SVIP another major p97 complex and if so,
what are its unique structural and functional features? How do
all the underexplored ‘‘minor” cofactors modulate these major
assemblies? Can the diversity of p97–cofactor complexes be fully
understood on the basis of bipartite and hierarchical binding
modes, or are additional, still unknown regulatory principles con-
tributing to p97 function? Which are the limitations that prevent
us from formulating a complete model describing the mutual influ-
ence of the D1 and D2 ATPase cycles, (sub)domain movements and
cofactor interactions? Finally, will we be able to devise successful
therapeutic strategies for patients suffering from IBMPFD once
we fully understand the pathogenic consequences of disease-
associated p97 variants on the structural, mechanistic and cellular
levels?
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